LH LH Labcorp Holdings Inc. 로딩 중... : 애널리스트의 강세 및 약세 의견

A news wire reports a broad list of price target increases from multiple analysts across dozens.

A news wire reports a broad list of price target increases from multiple banks across dozens.

JPMorgan raises its price target on Labcorp to 360 dollars from 330 dollars.

Labcorp raised its full-year outlook after reporting second-quarter earnings that exceeded.

Guidance raised for revenue and EPS, driven by strong organic growth in both diagnostics and BLS, with continued margin expansion.

Management raised guidance for the year, citing strong volume growth and margin expansion across both segments, with a positive outlook on the specialty testing and partnership pipeline.

Quest management noted that health plans are increasingly questioning paying hospital outreach labs 200-300% of the rates paid to independent labs, signaling a shift in pricing power away from hospital systems. — If health plans normalize rates, it could benefit Quest and LabCorp by reducing hospital competition on price, potentially accelerating hospital lab outsourcing.

Piper Sandler의 상당한 목표 주가 상향 조정에 따라 LabCorp(LH)를 롱하는 거래로, 전문 애널리스트의 주가 상승에 대한 확신을 시사합니다.

JP모건의 목표가 상향은 밸류에이션 모델에 대한 긍정적 수정과 주식의 예상 상승 여력을 시사합니다.

Management conveys strong confidence with positive guidance for 2026, driven by organic growth, launchpad savings, and improved margins, albeit with some headwinds from PAMA delay and ACA expirations fully incorporated.